Key Market Indicators
The Latvian market for blood and blood forming organs medicine is set to reach $55.3 million by 2026. In 2021, it was valued at $46.6 million, growing at an average of 2.7% year-on-year since 2006. Latvia was ranked 27th in the global rankings, with Estonia coming in ahead of it at $46.6 million. Germany, Italy, and South Korea took the top three spots. The prevalence of anemia in Latvia is expected to reach 1,560 hospital discharges in 2026, up from 1,500 discharges in 2021, representing a 0.6% year-on-year CAGR. Since 2017, the demand has grown 2.6% year-on-year. In 2021, Latvia was ranked 29th in the global rankings, with Slovenia ahead at 1,500 hospital discharges. Germany, the United Kingdom, and Poland took the top three spots.
